tbuckley/cabot-search huggingface dataset:
Characteristic dermoscopic features of primary cutaneous amyloidosis: a study of 35 cases
Authors: Y.Y. Chuang, D.D. Lee, C.S. Lin, Y.J. Chang, M. Tanaka, Y.T. Chang, H.N. Liu
Journal: British Journal of Dermatology (2012)

Primary cutaneous amyloidosis (PCA) is a relatively common skin disorder among Asians and South Americans. It is usually diagnosed clinically. However, for cases with atypical presentations, the diagnosis can be a challenge and skin biopsy may be necessary. Dermoscopy has been proved to be a valuable, noninvasive tool in the diagnosis of cutaneous pigmented diseases. Most lesions of PCA show hyperpigmentation and the major histopathological abnormalities of PCA occur in the epidermis and dermal papillae. Dermoscopy might be a powerful tool to provide valuable information for the diagnosis of PCA.We aimed to find characteristic dermoscopic features of PCA.Cases with typical clinical presentations of PCA, either macular or lichen subtypes, were included in this study. All were evaluated using a hand-held, polarized and nonpolarized dermoscope.A total of 35 patients with clinically diagnosed PCA were enrolled. Eighteen patients had lesions consistent with macular amyloidosis and 17 with lichen amyloidosus. We found two major dermoscopic patterns characteristic of PCA. The most common dermoscopic finding of PCA was a central hub, which could be either white or brown, surrounded by various configurations of pigmentation. For cases of lichen amyloidosus with prominent hyperkeratosis, the central hub was replaced by a scar-like morphology.This is the first study to report the characteristic dermoscopic features of PCA. We demonstrate that the use of a dermoscope may assist in achieving an accurate diagnosis of PCA.
The polyphosphate–factor XII pathway drives coagulation in prostate cancer-associated thrombosis
Authors: Katrin F. Nickel, Göran Ronquist, Florian Langer, Linda Labberton, Tobias A. Fuchs, Carsten Bokemeyer, Guido Sauter, Markus Graefen, Nigel Mackman, Evi X. Stavrou, Gunnar Ronquist, Thomas Renné
Journal: Blood (2015)
Endothelin receptor antagonists (ERAs) neutralize LPS-induced cytokine release from pulmonary vascular smooth muscle cells (PVSMCs) by down-regulation of CD14
Authors: David Jungck, Maria Feldmann, Chiara Wahl, Juergen Behr, Erich Stoelben, Juergen Knobloch, Andrea Koch
Journal: European Respiratory Journal (2013)

Bacterial infections induce COPD exacerbations by enhancing airway inflammation. Inflammation-induced vascular remodeling might drive the development of pulmonary hypertension (PH) in COPD. ERAs are approved for PH but their utility in COPD exacerbations is unknown.  Hypothesis: Bacterial endotoxin (LPS)-induced cytokine releases are reduced by ERAs in human PVSMCs.  Human PVSMCs were pre-incubated with the endothelin-A-receptor (ETAR)-selective inhibitor ambrisentan (AMB), with the ETBR-specific inhibitor BQ788 or with the dual blocker bosentan (BOS) before stimulation with clinically relevant long/smooth LPS (S-LPS), short/rough LPS (Re-LPS) or a mixture (M-LPS). Cytokine- and LPS-receptor (TLR4, CD14) expression were analyzed via ELISA and/or qRT-PCR.  All LPS forms induced IL-6-, IL-8- and GM-CSF-release (each p  PVSMCs contribute to infection-caused inflammation in COPD exacerbations. ETBR-blockade suppresses cytokines induced by smooth LPS due to sCD14 down-regulation. ERAs, particularly when targeting ETBR, might have therapeutic utility in COPD exacerbations with regard to attenuating inflammation-induced vascular remodeling.  Funded by Actelion Pharmaceuticals, Germany.
The Herby Study: a Phase 2 Open-Label, Randomized, Multicenter Study of Bevacizumab-Based Therapy in Pediatric Patients with Newly Diagnosed High-Grade Glioma
Authors: J. Grill, D. Hargrave, P. Varlet, T. Jaspan, C. Jones, M. Massimino, A. Cañete, A.A. Azizi, M. Le Deley, F. Saran, P. Morgan, G. Zahlmann, M. Zheng, S. Fuerst-Recktenwald, C. Berger, E. Bouffet, G. Vassal
Journal: Annals of Oncology (2014)
A phase I study of the raf kinase/VEGF-R inhibitor sorafenib in combination with bortezomib in patients with advanced malignancy
Authors: S. Kumar, R. S. Marks, R. Richardson, F. Quevedo, G. A. Croghan, S. N. Markovic, R. Qin, A. D. Tan, J. R. Molina, C. E. Erlichman, A. A. Adjei
Journal: Journal of Clinical Oncology (2008)

2569 Background: This phase I study was undertaken to define the toxicity and the maximum tolerated dose of the combination of sorafenib (BAY43–9006; a Raf kinase /VEGFR2 inhibitor) with bortezomib (a proteasome inhibitor) in patients (pts) with advanced solid tumors. The study also has an expanded cohort at MTD that will enroll pts with myeloma/ CLL to evaluate the pharmacodynamic/ pharmacokinetic parameters of therapy. Methods: Pts over 18 yrs with cytologic or histologic proof of unresectable solid tumors were enrolled to determine the MTD of the combination. Pts were treated with daily sorafenib and bortezomib on days 1, 4, 8 and 11 of a 3-week cycle. Toxicities were graded by the NCI CTC v.3. Pts are followed for a maximum of 3 mos after they go off treatment. The dose-escalation schema is in the table below. Results: Twelve pts (7 females, median age 63) have been enrolled on this study (6 each at dose level and 2). Tumor types included renal (3), lung (3), pancreas (2), breast (1), adrenal gland (1), melanoma (1) and spindle cell tumor (1). All pts are off treatment. Eight of these pts went off treatment due to disease progression (5 pts were treated at dose level 1 and 3 pts were treated at dose level 2). All 12 pts were evaluable for dose-limiting toxicity (DLT) analysis. DLT was seen in two pts at dose level 2 (one pt had grade 3 pain-abdominal and grade 4 lipase; and one pt had grade 3 vomiting). As a result, dose level 1 was declared as MTD. No grade 4 hematologic toxicities or grade 5 toxicities were seen. One grade 4 fatigue and lipase were reported in cycle 1. A median of 2 cycles of therapy (range 1–5) were administered. One pt had a partial response (renal), 4 had stable disease, 5 had progression and two pts were too early to evaluate for response. Conclusions: The combination of sorafenib and bortezomib appear to have antitumor activity and based on this study we recommend a dose of sorafenib at 200 mg twice daily continuously with bortezomib 1 mg/m2 on days 1, 4, 8, 11 of a 21 day cycle for further studies. Dose Escalation Schema Dose Level sorafenib (mg BID) bortezomib (mg/m2) 1 (Starting dose) 200 1.0 2 200 1.3 3 400 1.3 No significant financial relationships to disclose.
Cardiac output measured by rebreathing nitrous oxide for the follow-up of patient with pulmonary hypertension
Authors: Gael Deboeck, Robert McKenzie Ross, Joanna Pepke-Zaba
Journal: European Respiratory Journal (2011)

Introduction: Careful and frequent assessment is important for management of patient with pulmonary hypertension (PH). Cardiac output (CO) is one of the most relevant indexes to be assessed but cannot be performed routinely because of invasive determination. A simple non-invasive method, such as nitrous oxide inert gas rebreathing (REB) could be performed at every clinic visit.

Aims and objective: To evaluate the possibility to follow up CO by REB against thermodilution (TD) in patients with severe PH. (Dana Point class 1 and 4)

Methods: CO and Stroke volume (SV) were determined via TD and REB at two different visits and spearman correlation were applied.

Results: Good correlations were found between TD and REB Δ (visit 1 – visit 2) CO and ΔSV. TD and REB ΔCO and ΔSV correlated similarly with other indexes of clinical assessment.

View this table:

Correlation between TD and REB ΔCO and ΔSV and other Δ indexes





Conclusions: Nitrous oxide rebreathing CO measurement can be used as a monitioring tool of disease monitoring and potentially reduce the need for invasive CO measurement in patients with pulmonary hypertension.
Prevalence of respiratory symptoms in 7154 state road transport workers from India
Authors: Monica Barne, Komalkirti Apte, Sushmeeta Chhowala, Basant Pachisia, Bill Brashier, Sapna Madas, Jaideep Gogtay, Sundeep Salvi
Journal: European Respiratory Journal (2011)

Regular exposure to high levels of vehicular air pollutants is likely to predispose road transport workers (bus drivers, conductors and garage workers) to a high risk of respiratory illnesses.   Aim:  To study the prevalence of respiratory symptoms amongst road transport workers from Andhra Pradesh State of India.   Methods:  All employees present and willing to participate, from 24 randomly selected bus depots of 7 cities and towns of Andhra Pradesh State Road Transport Corporation (RTC) participated in this cross sectional study. Every individual was administered a respiratory health questionnaire that captured prevalence of respiratory symptoms.   Results:  7154 employees (41.4% drivers, 30.4% conductors, 15.9% garage workers, 7.9% office workers) participated in the study. Average age was 41.6±9.5 years. 27% of all the RTC employees had at least one respiratory symptom during the previous 3 months. Prevalences of rhinitis/rhino-sinusitis, cough, wheeze, breathlessness and chest pain/tightness were 14.7%, 10.5%, 8.3%, 7.9% and 5.6% respectively. Prevalence of respiratory symptoms were significantly higher in office workers (34.9%) as compared to drivers (24.2%; p   Conclusion:  Road transport workers have a high prevalence of respiratory symptoms with significantly greater values amongst office based workers and garage workers when compared to drivers and conductors.
Role of a Doxorubicin-Containing Regimen in Relapsed and Resistant Lymphomas: An 8-Year Follow-Up Study of EPOCH
Authors: Martin Gutierrez, Bruce A. Chabner, Debra Pearson, Seth M. Steinberg, Elaine S. Jaffe, Bruce D. Cheson, Antonio Fojo, Wyndham H. Wilson
Journal: Journal of Clinical Oncology (2000)

PURPOSE: Curative up-front regimens for non-Hodgkin’s lymphomas contain doxorubicin, vincristine, and cyclophosphamide, whereas salvage regimens generally contain non–cross-resistant agents. We hypothesized that up-front agents may be highly effective for salvage and developed an infusional regimen based on in vitro evidence of increased efficacy. PATIENTS AND METHODS: A prospective phase II study of etoposide, vincristine, and doxorubicin over 96 hours with bolus cyclophosphamide and oral prednisone (EPOCH) was performed in 131 patients with relapsed or resistant lymphoma. RESULTS: Seventy-nine percent of patients had aggressive histologies, 46% were considered high risk by the International Prognostic Index, and 34% had resistant disease. Eighty-eight percent of patients had received at least four of the agents in EPOCH, and 94% had received doxorubicin. In 125 assessable patients, 29 (24%) achieved complete responses and 60 (50%) achieved partial responses. Among 42 patients with resistant disease, 57% responded, and in 28 patients with relapsed aggressive de novo lymphomas, 89% responded with 54% complete responses. With a median follow-up of 76 months, the overall and event-free survivals (EFS) were 17.5 and 7 months, respectively. In 33 patients with sensitive aggressive disease who did not receive stem-cell transplantation, EFS was 19% at 36 months. Toxicity was primarily hematologic, with an 18% incidence of febrile neutropenia. No clinically significant cardiac toxicity was observed, despite no maximum cumulative doxorubicin dose. CONCLUSION: EPOCH is highly effective in patients who had previously received most/all of the same drugs and produces durable remissions in curable subtypes. Salvage regimens need not contain non–cross-resistant agents, and infusional schedules may partially reverse drug resistance and reduce toxicity.
Abstract 12412: Platelet Isoprostane Over-Production Enhances Platelet Function in Diabetic Patients Treated with Aspirin
Authors: Pasquale Pignatelli, Roberto Cangemi, Roberto Carnevale, Carmen Nigro, Francesco Angelico, Davide lauro, Stefania Basili, Francesco Violi
Journal: Circulation (2011)

Background- Aspirin modestly influences cardiovascular events in type 2 diabetic (T2DM) patients but the reason is unclear. We investigated whether in T2DM patients aspirin enhances platelet isopro...
Estimating Mortality Associated With Antipsychotics and Other Psychotropics
Authors: Roberto Lozano
Journal: JAMA Psychiatry (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Some US hospitals charge 10 times the cost of services, study finds
Authors: M. McCarthy
Journal: BMJ (2015)

Some US hospitals charge patients more than 10 times what Medicare pays for the same services, a new study has found.

For the study, published in the June issue of Health Affairs , Ge Bai from Washington and Lee University in Lexington, Virginia, and Gerard Anderson from Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland, compared what hospitals list as their charges for services with what are known as “Medicare allowable costs.”1

Looking at a sample of 4483 hospitals, the researchers found that in 2012 hospital charges were on average 3.4 times the Medicare allowable cost, meaning that when a hospital incurred $100 (£64; €89) of Medicare allowable costs, the hospital charged $340. When ranked based on how much they charged, the 10% of hospitals that charged the lowest had a charge …
Recurrent recruitment manoeuvres are required to maintain lung functions during low tidal volume ventilation of healthy mice
Authors: Lucy Kathleen Reiss, Stefan Uhlig
Journal: European Respiratory Journal (2011)

Mechanical ventilation (MV) of mice is widely used in experimental studies. However, conditions for ventilation of mice producing stable lung mechanics, blood pressure and heart rate over several hours are not well defined. In the present study, for the first time, MV with and without recruitment manoeuvres (RM) was compared in healthy mice. The effects of RM on a variety of physiological parameters and pulmonary inflammation were studied over 6h.  C57BL/6 mice were ventilated for 6h at low-V T =8mL/kg, f=180min -1  or high-V T =16mL/kg, f=90min -1  and 3% inspiratory CO 2 . FiO 2  was 0.5 and PEEP 2cmH 2 O. RM were performed with 30cmH 2 O for 1s every 5min, 60min or not at all. Lung mechanics were followed by the forced oscillation technique. Blood pressure (BP), ECG, heart frequency (HF), oxygen saturation and body temperature were monitored. Blood gases, histopathology, neutrophil recruitment, microvascular permeability and pro-inflammatory cytokines were examined.  MV with recurrent RM resulted in stable respiratory mechanics. Ventilation without RM worsened lung functions due to alveolar collapse, leading to impaired gas exchange. HF and BP were not affected. Microvascular permeability was highest in atelectatic lungs, whereas neutrophil recruitment and structural changes were strongest in lungs ventilated with high V T . Although IL-6 and KC were markedly elevated in all ventilated mice, levels were clearly reduced by recurrent RM. In contrast, TNF-α and IP-10 remained at baseline, indicating that only moderate lung injury was induced.  We conclude that recurrent RM are required to prevent atelectasis and resulting lung injury during mechanical ventilation of healthy mice.
A stratified phase II study of cetuximab for the treatment of recurrent glioblastoma multiforme: Preliminary results
Authors: J. Sadones, C. Chaskis, E. J. Joosens, L. A. Dhondt, J. Baurain, P. In ’t Veld, A. Michotte, J. De Grève, B. Neyns
Journal: Journal of Clinical Oncology (2006)

1558 Background: The Epidermal Growth Factor Receptor (EGFR) gene is frequently amplified and mutated in high-grade gliomas. We are investigating the activity of the EGFR-targeted monoclonal antibody cetuximab for the treatment of patients (pts) with recurrent glioblastoma multiforme (GBM) following surgery, radiotherapy and chemotherapy. Methods: Adult pts with recurrent GBM are allocated to two parallel treatment strata according to the amplification status of the EGFR gene (determined by FISH). According to a Simon two-stage phase II study design 1 response in 13 pts/stratum is required to continue recruitment and complete the second stage of pt recruitment. Cetuximab is administered at 400 mg/m 2 (2 hour infusion) day 1 and 250 mg/m 2 day 8 and for all subsequent weekly doses (1 hour infusion). Results: Between May and December 2005, 17 pts were recruited (10 without EGFR-ampl, 4 with EGFR-ampl and 3 under investigation); 4F/13M; median age 51 years, range 32–67). Recruitment is ongoing. Sixteen pts initiated study treatment; 1 pt withdrew consent before the initiation of therapy. Treatment related toxicity in the first 94 treatment cycles consisted of grade 1/2 folliculitis/dermitis in all treated pts. Grade 3 adverse events consisted of thrombocytopenia (n=1 pt), diminished consciousness (n=1 pt), dizziness/confusion (n=1 pt), infectious bronchopneumonia (n=1 pt), and infectious cellulitis (n=1 pt). Thirteen pts have been evaluated for response ≤ week 8 of study treatment. Eleven pts had progression of disease. Two patients had SD at 8 weeks (follow-up is ongoing). Conclusions: These preliminary data suggest that cetuximab can be safely administered to pretreated patients with recurrent GBM. Updated results regarding safety and activity as well as a correlative study of EGFR and PTEN expression and gene copy number of the GBM and response to cetuximab will be presented at the meeting. No significant financial relationships to disclose.
Histone Methylation Dynamics and Gene Regulation Occur through the Sensing of One-Carbon Metabolism
Authors: Samantha J. Mentch, Mahya Mehrmohamadi, Lei Huang, Xiaojing Liu, Diwakar Gupta, Dwight Mattocks, Paola Gómez Padilla, Gene Ables, Marcas M. Bamman, Anna E. Thalacker-Mercer, Sailendra N. Nichenametla, Jason W. Locasale
Journal: Cell Metabolism (2015)
Omalizumab prevents smooth muscle cell growth induced by asthmatic serum
Authors: Michael Roth, Jun Zhong, Michael Tamm
Journal: European Respiratory Journal (2014)

Background: Smooth muscle cell hypertrophy contributes significantly to airway wall thickness in asthma. It has been postulated that IgE in serum of asthma patients can stimulate airway smooth muscle cell proliferation even when no antigens are present. In this study we tested if the therapeutically used humanized anti-IgE antibody Omalizumab can reduce smooth muscle cell growth induced by asthmatic serum.

Methods: Using isolated primary human airway smooth muscle cells obtained from asthma patients (n=7) and non-asthmatic controls (n=7) we stimulated proliferation with either: i) 5% fetal calf serum (FCS), ii) pooled human serum (PHS), or iii) serum obtained from asthma patients (APS) over 3 and 5 days. Cell numbers were determined by manual cell counts using an improved Neugbaur chamber slide.

Results: Compared to FCS human sera were significant stronger inducers of cell proliferation (p<0.05), with APS being stronger than PHS (p<0.001) Furthermore, APS induced a significant faster proliferation of smooth muscle cells when the cells were obtained from asthma patients compared to non-asthma controls (p<0.01). Pre-incubation of APS with Omalizumab dose-dependently reduced the pro-proliferative effect in cells of both asthma patients and of non-asthma controls. The effect was also dependent on the length of pre-incubation of APS with Omalizumab. No reducing effect of Omalizumab was observed in cells stimulated with either FCS or PHS, suggesting that the proliferative effect of APS was directly dependent on the content of IgE.

Conclusion: Our data indicates that Omalizumab has the potential to reduce asthma related smooth muscle cell hypertrophy and thus reduce airway wall thickening in long term therapy.
A CASE OF PILI TORTL.
Authors: F. F. HELLIER, W. T. ASTBURY, FLORENCE O. BELL
Journal: British Journal of Dermatology (1940)

Journal Article A CASE OF PILI TORTL: With a Discussion of the Molecular Structure of the Condition and its Relationship to Monilethrix. Get access F. F. HELLIER, F. F. HELLIER Department of Dermatology. The General Infirmary, Leeds Search for other works by this author on: Oxford Academic Google Scholar W. T. ASTBURY, W. T. ASTBURY Textile Physics Department, University of Leeds Search for other works by this author on: Oxford Academic Google Scholar FLORENCE O. BELL FLORENCE O. BELL Textile Physics Department, University of Leeds Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology and Syphilis, Volume 52, Issue 6, 1 June 1940, Pages 173–176, https://doi.org/10.1111/j.1365-2133.1940.tb09908.x Published: 01 June 1940
The effects of angiotensin II and related peptides on intracellular Ca2+ release in human lung fibroblasts
Authors: Samantha Maitland, Anthony Sampson, Jane Warner, David Hall
Journal: European Respiratory Journal (2013)

Introduction.  Fibroblasts are a key cell type responsible for the deposition of extracellular matrix (ECM) in idiopathic pulmonary fibrosis (IPF). Angiotensin II (AngII) increases fibroblast proliferation and ECM deposition, but little is known about other angiotensin peptides, such as Ang(1-7), or their effects on fibroblasts.   Aim.  To determine the effects of angiotensin peptides on intracellular Ca 2+  release in human lung fibroblasts (HLFs).   Method.  Eight angiotensin peptides were tested for their ability to mobilise calcium in HLFs using a FLIPR assay, and the EC 50  calculated. Peptides that failed to mobilise Ca 2+  were retested as antagonists.   Results.  AngI, AngII, AngIII and Ang(3-8) mobilised Ca 2+  with EC 50  values ranging from 22nM for AngII to >10μM for Ang(3-8). Telmisartan (10nM) completely abolished the Ca 2+  response in all cases, indicating that all four peptides were acting via angiotensin receptor 1 (ATR1). Neither PD-123319 (ATR2 antagonist) nor A-779 (Ang(1-7) antagonist) had any effect on Ca 2+  mobilisation. Pretreatment of the fibroblasts with 10μM Ang(1-7) or Ang(1-9) caused 43% and 60% inhibition of the maximal Ca 2+  response to AngII respectively, with an IC 50  of 2.9μM estimated for Ang(1-9) in this assay.   Conclusion.  Four angiotensin peptides generate a Ca 2+  response in HLFs via ATR1; this Ca 2+  release may influence functional responses such as proliferation and ECM deposition. Ang(1-7) and Ang(1-9) inhibit this calcium mobilisation in a manner that is not consistent with simple competitive antagonism; this mechanism of inhibition requires further investigation.